Literature DB >> 10086783

Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease.

J Nishi1, K Arimura, A Utsunomiya, S Yonezawa, K Kawakami, N Maeno, O Ijichi, N Ikarimoto, M Nakata, I Kitajima, T Fukushige, H Takamatsu, K Miyata, I Maruyama.   

Abstract

To evaluate the possible involvement of vascular endothelial growth factor (VEGF) in the pathogenesis of Castleman's disease, we studied VEGF levels in sera and supernatants of cultured lymph nodes from two patients with the plasma cell type of Castleman's disease, and analysed the expression of VEGF immunohistochemically in the lymph nodes. Clinically, one patient was classified as the localized type and the other as the multicentric type. Histologically, mature plasma cells and hyalinized vessels were prominent in the interfollicular region. The VEGF levels of the sera and the supernatants of cultured lymph nodes of both patients were higher than those of normal controls. VEGF was strongly expressed in plasma cells in the interfollicular region of the lymph nodes of both patients, but rarely in normal lymph nodes. Our results suggest that VEGF may be involved in the marked vascular proliferation in the interfollicular region of the lymph nodes of the plasma cell type of Castleman's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10086783     DOI: 10.1046/j.1365-2141.1999.01208.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  24 in total

1.  Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats.

Authors:  Subhash C Verma; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

Review 2.  Castleman's disease: from basic mechanisms to molecular therapeutics.

Authors:  Hazem E El-Osta; Razelle Kurzrock
Journal:  Oncologist       Date:  2011-03-25

Review 3.  HIV-associated multicentric Castleman disease.

Authors:  Deepa Reddy; Ronald Mitsuyasu
Journal:  Curr Opin Oncol       Date:  2011-09       Impact factor: 3.645

4.  Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.

Authors:  Om Prakash; O Rama Swamy; Xiochang Peng; Zhen-Ya Tang; Li Li; Janet E Larson; J Craig Cohen; Javed Gill; Gist Farr; Suizhao Wang; Felipe Samaniego
Journal:  Blood       Date:  2005-01-21       Impact factor: 22.113

5.  Castleman's disease associated with a cerebellar chordoid meningioma and intestinal lymphangiectasia.

Authors:  Chul Jin Jeon; Mi Jin Kim; Jong Seung Lee; Ji Hyuk Lee; Doo-Sik Kong; Hyung Jin Shin; Yeon Lim Suh; Kyoung Mee Kim; Yon Ho Choe
Journal:  Childs Nerv Syst       Date:  2010-06-22       Impact factor: 1.475

Review 6.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  Does Kaposi's sarcoma predict multicentric Castleman disease in the presence of generalized lymphadenopathy?

Authors:  Homam Alkaied; Kassem Harris; Dany Elsayegh; Inga Khachaturova; Michael Awasum; Seema Varma
Journal:  Med Oncol       Date:  2011-04-07       Impact factor: 3.064

8.  Pelvic Castleman's disease presenting as an adnexal tumor in a young woman.

Authors:  Jisun Lee; Jiheum Paek; Yong Hee Lee; Tae Wook Kong; Suk-Joon Chang; Hee-Sug Ryu
Journal:  Obstet Gynecol Sci       Date:  2015-07-16

9.  Histologic and Laboratory Characteristics of Symptomatic and Asymptomatic Castleman Disease in the Pediatric Population.

Authors:  Karen M Chisholm; Mark D Fleming
Journal:  Am J Clin Pathol       Date:  2020-05-05       Impact factor: 2.493

Review 10.  KSHV: pathways to tumorigenesis and persistent infection.

Authors:  Louise Giffin; Blossom Damania
Journal:  Adv Virus Res       Date:  2014       Impact factor: 9.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.